Biomea Fusion, Inc.
Biomea Fusion, Inc. (BMEA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BMEA · as of Jun 8, 2026
Key Statistics
Explore Biomea Fusion, Inc. Data
bmea stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 76.9%
The BMEA analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $20.20, representing +1656.52% upside from the current price of $1.15.
Competitors & Peers
bmea competitorsBMEA
ADVM
ALXO
CAMP
CBUS
GUTSStock Performance
Full HistoryAbout Biomea Fusion, Inc.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals sufferi…
what is biomea fusion, inc. · bmea stock overview · biomea fusion, inc. company profile · who is biomea fusion, inc. ceo · bmea NASDAQ · biomea fusion, inc. headquarters · biomea fusion, inc. business segments
About Stock Overview & Key Data
Biomea Fusion, Inc. (BMEA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 16, 2021. As of the latest trading session, BMEA stock price is $1.15, with a market capitalization of $68.4M. The stock has returned -56.27% over the past 12 months and -7.26% year-to-date.
According to 13 Wall Street analysts, the consensus rating for Biomea Fusion, Inc. stock is Buy, with an average 12-month price target of $20.20. In fiscal year 2025, Biomea Fusion, Inc. reported revenue of — and net income of -$61.8M. For detailed data — including Biomea Fusion, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Biomea Fusion, Inc. (BMEA) stock price is $1.15. The stock is traded on NASDAQ under the ticker symbol BMEA. The 52-week range is $0.87 – $3.08.